PRENATAL ANEUPLOIDY TEST RESULTS OF OTHER CHROMOSOMES OR MATERNAL BLOOD TEST FOR FETAL DNA ( MBFD )

CHROMOSOME 1, CHROMOSOME 2, CHROMOSOME 3, CHROMOSOME 4, CHROMOSOME 5, CHROMOSOME 6, CHROMOSOME 7, CHROMOSOME 8, CHROMOSOME 9, CHROMOSOME 11, CHROMOSOME 12, CHROMOSOME 14, CHROMOSOME 15, CHROMOSOME 16, CHROMOSOME 17, CHROMOSOME 19, CHROMOSOME 20, CHROMOSOME 22

CHROMOSOME 13, CHROMOSOME 18, CHROMOSOME 21

THIS TEST SCREENS A MATERNAL BLOOD SAMPLE FOR CHROMOSOME ANUPLOIDY OF FETAL DNA USING FOLLOWING METHODOLOGY

1. EXTRACTION OF CELL FREE FETAL DNA FROM THE MATERNAL BLOOD SAMPLE
2. HIGH THROUGH PUT SEQUENCING OF THE EXTRACTED CELL FREE FETAL DNA
3. CALCULATION OF MOLECULAR MASS OF FETAL DNA IN ALL CHROMOSOMES

BASED ON THE SCOPE THE MBFD TEST CAN DETECT THE FOLLOWING

1. WHOLE GENOME – HUMAN CHROMOSOMES
2. COMMON CHROMOSOMAL ABNORMALITIES — TRISOMY 13 (PATAU ‘S SYNDROME ), TRISOMY 18 (EDWARD’S SYNDROME), TRISOMY 21 (DOWN’S SYNDROME )

THIS TEST SPECIALIZATION IN THE RESEARCH AND DEVELOPMENT OF PROFESSIONAL AND HIGH QUALITY SERVICE IN THE FIELD OF CLINICAL GENETIC TESTING. THE TEST ANALYSIS CALCULATING CELL FREE DNA EXTRACTED FROM THE MATERNAL BLOOD SAMPLE. THE TESTES INDICATED FOR USE IN PREGNANT WOMAN WITH INCREASED RISK FOR CHROMOSOMAL ANEUPLOIDY. CHROMOSOMAL ANEUPLOIDY CAN THEN BE DETECTED USING BIOINFORMATICS ANALYSIS, WHERE THE DETECTION RATE AND SEVERITY ARE OVER 99%. THE ACCURACY AND QUALITY OF TASTE MAY BE AFFECTED BY IMPROPER  BLOOD SAMPLE COLLECTION, STORAGE, TRANSPLANTATION.

TEST METHOD

THE TEST EMPLOYS A NON-INVASIVE AND LOWER RISK METHOD FOR THE ACQUISITION OF A FETAL DNA SAMPLE. CIRCULATING CELL FREE DNA WAS PURIFIED FROM THE PLASMA COMPONENT OF ANTICOAGULATED 10 ML OF MATERNAL WHOLE BLOOD. IT WAS THEN CONVERTED INTO GENOMIC DNA LIBRARY FOR NEXT GENERATION SEQUENCING AND THEN ANALYSIS FOR DETERMINATION OF CHROMOSOMAL 21, 18, 13 ANEUPLOIDIES.